The Present research was conducted to evaluate the ability of Deferasirox and Deferiprone (L1) chelators as single and combined therapies in removing mercury from biological system. Mercury at two doses of 10 (low dose ...

این مقاله به سنتز، شناسایی ساختاری و مطالعات ضدسرطانی کمپلکس آهن (III)-دیفریپرون می پردازد.

Chelation therapy has a long history of use in clinical toxicology to remove heavy metal toxicity from the body. The present research aimed to investigate the potential efficiency of Deferasirox and Deferiprone in removing ...

In

this study, we evaluated the anti-proliferative and apoptotic effects of copper complexes

including curcumin and ruthenium-curcumin complex against human cervix epithelial

carcinoma (HeLa), cell ...

The Cu(II) complexes [Cu(Tppz)(Dipic)] ⋅ 8H2O (I) and [Pb2(Tppz)Cl4]n (II), where Tppz,

H2Dipic are 2,3,5,6-tetrakis(2-pyridyl)pyrazine, dipicolinic acid, respectively, have been synthesized and

characterized ...

The aim of present study was to examine new role of Deferasirox as an important class of iron chelators as anticancer agents due to its ability to chelate with Iron.

In this study,

we evaluated the cytotoxicity and apoptotic effects of ruthenium, copper, and cobalt

complexes including 3-Hydroxyflavone against human cervix epithelial carcinoma

(HeLa) cell line and ...

Abstract

The hypothesis that two known chelators deferasirox (4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) and desferrioxamine (DFO) might be more efficient as combined treatment than as monotherapies ...